- $180.74m
- -$151.68m
- $141.54m
- 77
- 60
- 32
- 56
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 64.4 | 134 | 168 | 161 | 142 |
Cost of Revenue | |||||
Gross Profit | 44 | 86.4 | 104 | 99.4 | 89.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 70.5 | 139 | 249 | 276 | 230 |
Operating Profit | -6.09 | -5.19 | -80.7 | -116 | -88.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.38 | -2.55 | -71.8 | -120 | -86.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.18 | -3.11 | -72.7 | -121 | -87.2 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -6.18 | -3.11 | -72.4 | -120 | -87.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -66.9 | -203 | -72.4 | -120 | -87.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.168 | -0.6 | -0.156 | -0.263 | -0.176 |